Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update - Key Catalysts ahead with multiple Value Generating Readouts -- Expects to Report Phase 1/2 Data Releases with Oral Fadraciclib -- Advancing single-agent Efficacy with Differentiated Oral Plogosertib...

AMD Details Strategy to Deliver Best-in-Class Growth and Strong Shareholder Returns at 2020 Financial Analyst Day — High-performance computing leadership, disruptive solutions and sustained execution to drive significant growth across $79 billion data center, PC and gaming markets1 — SANTA CLARA, Calif., March ...